TBNHealth
STAT+: Pharmalittle: We’re reading about a cancer vaccine, an experimental pancreatic cancer drug, and more
Publication: STAT
Author: Ed Silverman
Source published: 23/10/2026, 13:45:14 UTC
Briefing created: 23/10/2026, 13:53:17 UTC
Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 23/10/2026, 13:51:24 UTC.
Briefings
A clinical trial involving a personalized mRNA cancer vaccine for melanoma patients showed a 42% reduction in disease recurrence compared to standard treatment, with patients living significantly longer without cancer returning. The vaccine was announced by Merck and Moderna in August, though specific benefit magnitudes were withheld until a scheduled presentation. A U.S. judge later granted a request to intervene in a lawsuit regarding a government rebate pilot program, allowing AbbVie, Bristol Myers Squibb, and Boehringer Ingelheim to challenge the 340B Drug Discount Program.
Key points
- A clinical trial testing a personalized mRNA cancer vaccine reduced the risk of disease recurrence in melanoma patients by 42% compared to standard treatment.
- Merck and Moderna announced the vaccine's success in August, with details including benefit magnitude withheld until a scheduled presentation at the European Society of Medical Oncology.
Context
STAT+ reports on a breakthrough in cancer treatment involving a personalized mRNA vaccine for melanoma, highlighting a 42% reduction in recurrence risk. The vaccine was previously announced by Merck and Moderna in August, with specific benefit details released after a judge intervened in a lawsuit over a government rebate pilot program.
Limitations
Specific benefit magnitudes of the vaccine were withheld until a scheduled presentation at the European Society of Medical Oncology. A U.S. judge granted a request to intervene in a lawsuit regarding a government rebate pilot program, allowing multiple drugmakers to challenge the 340B Drug Discount Program. Evidence is limited to reported trial results and legal interventions, with no data on long-term outcomes or broader applicability to other cancer types.
Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 23/10/2026, 13:53:17 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.
View archived briefing on IPFS
bafybeihgcjufi3aiqoxgpr2t6sxhckssy6dtcdhf5pu4feozhicgslgt2q